Invitrogen Sues Incyte in Patent Dispute | GenomeWeb

SAN FRANCISCO, Oct. 18 – Contending patent violations, Invitrogen filed suit against Incyte Genomics Wednesday in the US District Court of Delaware, Invitrogen told GenomeWeb .

The primary patent in contention is Invitrogen’s SuperScript form of RNAse H minus reverse transcriptase, which Invitrogen said was sold to Incyte under a research-use-only license.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."